Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05163067

Combined Aerobic Exercise and Cognitive Training in Seniors With Genetic Susceptibility for Alzheimer's Disease

The study aims to investigate the effect of a long-term combined aerobic exercise and cognitive training program on cognitive function, daily function, psychosocial status, and neural plasticity in seniors with genetic susceptibility for Alzheimer's Disease.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Disease Attributes Disease Susceptibility Genetic Predisposition to Disease Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Tauopathies

Age range

50 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Xuanwu Hospital

Beijing, China

About this study

Alzheimer's disease (AD) is the most common type of dementia and the leading cause of disability in people older than 65 years worldwide. However, there is no effective disease-modifying therapy currently. Therefore, improvement of cognitive function in people at risk and, potentially, prevention of cognitive decline has been gaining attraction.

Our previous research reported a model of a combination single nucleotide polymorphism (SNP) (rs3777215, rs234434, rs71352238, and rs4420638) can predict AD onset with high performance, which is useful to identify people at risk for AD and thus allows for timely treatment and prevention.

Both aerobic exercise and cognitive training have been demonstrated beneficial effects on cognition in subjects with AD and healthy populations. Moreover, the synergistic effects of the combination have been proven recently. However, the effect of combined aerobic exercise and cognitive training on seniors with genetic susceptibility for AD remains to be elucidated. Herein, this study aims to

  • assess the effects of long-term combined aerobic exercise and cognitive training on cognitive function, daily function, psychosocial status, and neural plasticity in seniors with single nucleotide polymorphism of rs3777215, rs234434, rs71352238, and rs4420638.
  • confirm the predictive value of the SNP model for AD in a longitudinal setting.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Mandarin-speaking subjects.
  • Not clinically demented.
  • Meeting the cutoff values of MMSE and CDR.
  • With positive variation of rs3777215, rs234434, rs71352238, and rs4420638.

Exclusion criteria

  • Had major neurologic diagnosis (e.g., Parkinson's disease, stroke, encephalitis, and epilepsy) or other condition that might impair cognition or confound assessments.
  • Had a history of psychotic episodes or had major depression (Hamilton Depression Rating Scale score > 24 points).
  • Had severe systemic diseases, such as tumors, cardiovascular or orthopedic disorder that can affect the ability to perform the proposed intervention tasks.

Treatment and study plan

Combined aerobic exercise and cognitive training program

Behavioral

Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.

Primary outcomes

  1. Change in cognitive function over time as assessed by the Montreal Cognitive Assessment (MoCA)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    MoCA will be performed to evaluate the cognition of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 30, with higher values indicating better cognition.

  2. Change in cognitive function over time as assessed by Mini Mental State Examination (MMSE)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    MMSE will be performed to evaluate the cognition of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 30, with higher values indicating better cognition.

  3. Change in cognitive function over time as assessed by Clinical Dementia Rating (CDR)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    CDR will be performed to evaluate the cognition of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 18, with higher values indicating worse cognition.

  4. Change in cognitive function over time as assessed by Verbal Fluency Test

    Time frame: baseline time, year 1, year 3, year 5, year 7

    Verbal Fluency Test will be performed to evaluate the semantic memory function of participants at the enrollment and year 1, year 3, year 5, year 7. Participants are asked to produce as many animals as possible within 1 minute. The score is the number of animals, with higher scores indicating better cognition.

  5. Change in cognitive function over time as assessed by Digit Span Test-Forward and Backward

    Time frame: baseline time, year 1, year 3, year 5, year 7

    Digit Span Tests will be performed to evaluate the working memory of participants at the enrollment and year 1, year 3, year 5, year 7. The total scores are twelve for each test, with higher values indicating better cognition.

  6. Change in cognitive function over time as assessed by Trail-Making Test Parts A and B (TMT-A and TMT-B)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    TMT-A and TMT-B will be performed to evaluate the executive function of participants at the enrollment and year 1, year 3, year 5, year 7. Scoring is based on time taken to complete the test (e.g., 35 seconds yielding a score of 35), with lower scores indicating better cognition.

  7. Change in cognitive function over time as assessed by Boston Naming Test (BNT)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    BNT will be performed to evaluate the language function of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 30, with higher values indicating better cognition.

  8. Change in cognitive function over time as assessed by California Verbal Learning Test (CVLT)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    CVLT will be performed to evaluate the memory function of participants at the enrollment and year 1, year 3, year 5, year 7. Participants are asked to finish immediate recall, delayed recall, and delayed recognition tasks in the test, with higher scores indicating better cognition.

  9. Change in cognitive function over time as assessed by the Rey-Osterrieth Complex Figure Test (ROCF)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    ROCF will be performed to evaluate the visuospatial function and other cognition domains of participants at the enrollment and year 1, year 3, year 5, year 7. Participants are asked to produce a complicated line drawing, with higher scores indicating better cognition.

  10. The area under curve of the SNP model (rs3777215, rs234434, rs71352238 and rs4420638) for the accurate diagnosis of AD

    Time frame: up to 7 years

    The area under curve is used to show the ability of the SNP model (rs3777215, rs234434, rs71352238 and rs4420638) to diagnose AD. The value of area under curve is higher, then the ability of the SNP model to diagnose AD is stronger.

Secondary outcomes

  1. Change in whole brain volume as accessed by brain MRI

    Time frame: baseline time, year 1, year 3, year 5, year 7

    Brain MRI will be performed to evaluate the whole brain volume of participants at the enrollment and year 1, year 3, year 5, year 7. Whole brain volume is measured in mL and determined by Freesurfer analysis. There is no defined maximum. Zero is the theoretical minimum. Greater number indicates larger brain volume.

  2. Change in daily function over time as assessed by Activities of daily living (ADL)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    ADL will be performed to evaluate the daily function of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 14 to 64, with lower values indicating better function.

  3. Change in anxiety over time as assessed by Hamilton Anxiety Rating Scale (HAMA)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    HAMA will be performed to evaluate the daily function of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 64, with higher values indicating more severe anxiety.

  4. Change in depression over time as assessed by Hamilton Depression Scale (HAMD)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    HAMD will be performed to evaluate the daily function of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 96, with higher values indicating more severe depression.

  5. Change in neuropsychiatric symptoms over time as assessed by Neuropsychiatric Inventory Questionnaire (NPI-Q)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    NPI-Q will be performed to evaluate the daily function of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 144, with higher values indicating more severe neuropsychiatric symptoms.

Study contacts

Contact information is provided by the study sponsor or research team.

Longfei Jia, MD,PhD

CONTACT

[email protected]

+86 10 83199456

Sponsors and collaborators

Lead sponsor

Xuanwu Hospital, Beijing

Other

Registry information

Official study title

Combined Aerobic Exercise and Cognitive Training for Alzheimer's Disease Prevention in Seniors With Genetic Susceptibility Estimated by Polygenic Risk Models: Cognition and Neural Plasticity Effects

Important dates

Study start
2024
Primary completion
2034
Study completion
2034
First posted
Dec 20, 2021
Registry last updated
Jul 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.